ArticleRetina (Philadelphia, Pa.)2026
MODELING NATURAL HISTORY AND COST-EFFECTIVENESS OF GENE-AGNOSTIC TREATMENT IN RETINITIS PIGMENTOSA.
Article in Retina (Philadelphia, Pa.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTreatment options for retinitis pigmentosa (RP) have been limited. A new generation of innovative but potentially expensive treatments under development may halt or reverse disease progression.
methodsUsing an existing database, a closed-cohort microsimulation model of all genetic subtypes of RP was conducted from a U.S. societal perspective. A hypothetical gene-agnostic therapy was compared with standard care at age 30. Outcomes included VF and VA progression; incremental cost-effectiveness ratio (ICER: dollars per quality-adjusted life-year (QALY) gained); and lifetime medical and productivity-related costs.
resultsBaseline cohort (age 30, N = 381; mean VA logMAR, 0.26 (20/36); mean VF sum total degrees (III4e), 749). By age 45, 79% of patients with untreated RP reached legal blindness or worse, compared with significantly delayed progression with treatment. ICER of gene-agnostic therapy was $158,554/QALY, yielding better outcomes compared with untreated RP (20.5 vs. 16.7 QALYs) and substantial indirect cost savings ($691,961) if a drug price of $1.5 million was assumed.
conclusionA gene-agnostic treatment for RP with drug price of $1.5 million (both eyes) may be cost-effective for most types of RP, particularly with earlier initiation. These findings can inform clinical, economic, and health policy decisions, potentially supporting early intervention strategies and resource allocation for novel RP treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.